<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?OLF?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Pharmacol Rep</journal-id><journal-id journal-id-type="iso-abbrev">Curr Pharmacol Rep</journal-id><journal-title-group><journal-title>Current Pharmacology Reports</journal-title></journal-title-group><issn pub-type="epub">2198-641X</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7302922</article-id><article-id pub-id-type="publisher-id">218</article-id><article-id pub-id-type="doi">10.1007/s40495-020-00218-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Hot Topic</subject></subj-group></article-categories><title-group><article-title>COVID-19 Drug Treatment in China</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fan</surname><given-names>Linzi</given-names></name><address><email>felicitafan@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Shuang</given-names></name><address><email>jsjiang111@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Xinrong</given-names></name><address><email>yangxinrongx@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Wang</surname><given-names>Zhibin</given-names></name><address><email>wzbmailbox@hljucm.net</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Yang</surname><given-names>Chunjuan</given-names></name><address><email>chunjuanyang@hrbmu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.410736.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 2204 9268</institution-id><institution>Department of Pharmaceutical Analysis and Analytical Chemistry, College of Pharmacy, </institution><institution>Harbin Medical University, </institution></institution-wrap>No. 157 Baojian Road, Nangang District, Harbin, 150081 Heilongjiang People&#x02019;s Republic of China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.412068.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 1759 8782</institution-id><institution>Key Laboratory of Chinese Materia Medica (Ministry of Education), </institution><institution>Heilongjiang University of Chinese Medicine, </institution></institution-wrap>Harbin, 150040 Heilongjiang China </aff></contrib-group><pub-date pub-type="epub"><day>19</day><month>6</month><year>2020</year></pub-date><fpage>1</fpage><lpage>9</lpage><permissions><copyright-statement>&#x000a9; Springer Nature Switzerland AG 2020</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><abstract id="Abs1"><sec><title>Purpose of Review</title><p id="Par1">An unprecedented outbreak of the novel coronavirus in China (COVID-19) occurred in December 2019, and then engulfed the entire world, presenting a significant and urgent threat to global health. Many research institutes have been involved in the development of drugs and vaccines against COVID-19.</p></sec><sec><title>Recent Findings</title><p id="Par2">At present, the strategy of new use of old drugs is mainly used to screen candidate drugs against the novel coronavirus (later termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)) and inhibit excessive immune response. Related research has made great progress.</p></sec><sec><title>Summary</title><p id="Par3">In this review, we summarize the drugs used for COVID-19 treatment in China based on the emerging basic and clinical data. It is hoped that this review will be useful to provide guidance for the prevention, treatment, and control of COVID-19.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>Medical treatment</kwd><kwd>New drug research and development</kwd></kwd-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par4">An outbreak of a series of pneumonia cases associated with a novel coronavirus has been reported in Wuhan, Hubei Province, China, since December 2019 [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. It is highly contagious and has rapidly spread to the entire China and multiple other countries worldwide since then [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref>]. On January 5, 2020, Professor Zhang of Fudan University completed virus sequencing and submitted the first novel coronavirus genome sequence to the National Bank of the US National Center for Biotechnology Information (Acc. No. MN908947). After that, this global health threat was officially and internationally named SARS-CoV-2 by the World Health Organization (WHO) on February 11, 2020 [<xref ref-type="bibr" rid="CR7">7</xref>]. On January 30, 2020, the WHO declared the Chinese outbreak of COVID-19 to be a public health emergency of international concern, which means the outbreak of COVID-19 raised intense attention internationally; all countries around the world should be prepared for a potential global outbreak [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>]. Up to now, there had been 1,524,334 confirmed cases, 340,335 cured, and 88,468 deaths (as of April 9, 2020). Clinically, most patients developed mild symptoms of dry cough, dyspnea, fever, and bilateral lung infiltrates on imaging [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref>]. Besides, numbers of researches have confirmed that while the mortality rate of the elderly and patients with underlying diseases is high, that of the young is relatively low through the deadliest outbreak of COVID-19 [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par5">There are six strains of coronaviruses that are confirmed infectious to humans, which are named for their coronary appearance with positive single-stranded RNA genomes [<xref ref-type="bibr" rid="CR15">15</xref>]. Similar to SARS and MERS, SARS-CoV-2 is a kind of highly pathogenic coronavirus that could cause severe respiratory illness and even death [<xref ref-type="bibr" rid="CR16">16</xref>]. However, SARS-CoV-2 has higher transmissibility from human to human comparatively, which makes humans vulnerable to infection and makes it harder to get this outbreak under control [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par6">As the epidemic is getting worse, the control of COVID-19 presents multiple challenges in the short term [<xref ref-type="bibr" rid="CR20">20</xref>]. Nevertheless, no specific antiviral medicine is available either to treat or to prevent the aggravation of COVID-19 [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. More potent antiviral drugs are urgent to be developed [<xref ref-type="bibr" rid="CR23">23</xref>]. It usually takes about 12 to 15&#x000a0;years for a new drug transitioning from development to market, which is a fairly long process. Therefore, it is not feasible to study antinovel coronavirus drugs from the beginning to get a direct effect on the prevention and control of this outbreak. Only by adopting the strategy of &#x0201c;old drugs for new use,&#x0201d; that is, finding effective drugs against novel coronavirus from existing drugs on the market, making it be rapidly applied to clinical practice [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. COVID-19&#x02019;s therapeutic strategies mainly relied on the experience of clinicians [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. Up to now, some medicines are confirmed clinically to be effective in eliminating SARS-CoV-2 and improving symptoms [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. Among them, traditional Chinese medicines have received broad adoption, especially in treating cases of mild symptoms [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. In this review, we summarized the drugs used for COVID-19 treatment in China based on the emerging basic and clinical data. It is hopeful that this review will be useful to provide guidance for the prevention and control of COVID-19.</p></sec><sec id="Sec2"><title>Traditional Chinese Medicine</title><p id="Par7">Although there is no specific medicine recommended to prevent or treat the novel coronavirus to date, when the outbreak started, Chinese medicine (CM) approaches including oral administration of preventive herbal formulae, wearing CM sachets, and indoor herbal medicine fumigation were recommended for prevention and treatment and have shown pretty good effects [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Under the guidance of clinical experience, the treatment for COVID-19 was divided into medical observation period and clinical treatment period (confirmed cases). The clinical treatment period (confirmed cases) is further stratified into four manifestations including mild case (cold-damp constraint in the lung pattern or damp-heat accumulation in the lung pattern), moderate case (damp-toxin constraint in the lung pattern or cold-damp obstructing the lung pattern), severe case (epidemic toxin blocking the lung pattern or blazing of both Qi and Ying patterns), and critical case (internal blockage and external desertion pattern) followed by a rehabilitation stage (lung and spleen qi deficiency patterns or deficiency of both qi and yin patterns). Depending on the patient&#x02019;s pathological condition, different medications or prescriptions were used at different stages [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. At present, a total of 23 different Chinese medicines are recommended nationwide for the treatment of mild, severe, and critical symptoms [<xref ref-type="bibr" rid="CR35">35</xref>]. According to prescriptions and standards, under the guidance of traditional Chinese medicine theory, Chinese medicines were made into certain dosage forms, which could be directly used for the prevention and treatment of diseases [<xref ref-type="bibr" rid="CR36">36</xref>&#x02013;<xref ref-type="bibr" rid="CR42">42</xref>]. Those Chinese medicine formulation used on COVID-19 are listed in Table <xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Reported use of Chinese medicine formulations on COVID-19</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Proprietary Chinese medicines</th><th>Composition</th><th>Application stage</th><th>Indications</th></tr></thead><tbody><tr><td>Jinhua Qinggan granules</td><td>Jin-yin-hua, shi-gao, ma-huang, xing-ren, huang-qin, lian-qiao, zhe-bei-mu, zhi-mu, niu-bang-zi, qing-hao, bao-he, gan-cao</td><td>Medical observation period&#x02014;clinical manifestation 2</td><td>Fever, headache, sore body, sore throat, cough, bad wind or cold, runny nose, red tongue, thin yellow fur</td></tr><tr><td>Huoxiangzhengqi capsule (pill, oral liquid)</td><td>Cang-zhu, chen-pi, hou-pu, bai-zhi, fu-ling, da-fu-pi, ban-xia, gan-cao, huo-xiang, and zi-su-ye</td><td>Medical observation period&#x02014;clinical manifestation 1</td><td><p>Aversion to cold without sweat, headache body weight, limb pain, chest</p><p>Diaphragm full, thirst not to drink, loose stools, drowning short, and yellow</p></td></tr><tr><td>Lianhua Qingwen capsules (granules)</td><td>Lian-qiao, jin-yin-hua, ma-huang, xing-ren, shi-gao, ban-lan-gen, guan-zhong, yu-xing-cao, huo-xiang, da-huang, hong-jing-tian, bao-he, gan-cao</td><td>Medical observation period&#x02014;clinical manifestation 2</td><td>Fever or high fever, chills, muscle soreness, stuffy nose, runny nose, cough, headache, dry throat, sore throat, red tongue, yellow, or greasy fur</td></tr><tr><td>Jingyin granules</td><td>Jing-jie, yin-hua, niu-bang-zi, da-qing-ye, si-ji-qing</td><td>/</td><td>Clearing heat and detoxifying, moistening lung, and throat</td></tr><tr><td>Shufeng Jiedu capsules (granules)</td><td>Hu-zhang, lian-qiao, ban-lan-gen, chai-hu, bai-jiang-cao, ma-bian-cao, lu-gen, gan-cao</td><td>Medical observation period&#x02014;clinical manifestation</td><td>Fever, bad wind, sore throat, headache, stuffy nose, runny nose, cough, red tip of tongue, thin white dry or yellow tongue coating, floating pulse</td></tr><tr><td>Xiyanping injection</td><td>Chuan-xin-lian</td><td>Clinical treatment period&#x02014;severe</td><td>Severe fever and polydipsia, dyspnea and anhelation, delirium, blurred vision, rash, or hematemesis and epistaxis, or convulsion of the limbs. Tongue with little or no fur, deep and count pulse, or large and rapid pulse</td></tr><tr><td>Xuebijing injection</td><td>Hong-hua, chi-shao, chuan-xiong, dan-shen, dang-gui</td><td>Clinical treatment period&#x02014;severe and critical</td><td>Severe fever and polydipsia, dyspnea and anhelation, delirium, blurred vision, rash, or hematemesis and epistaxis, or convulsion of the limbs. Tongue with little or no fur, deep and count pulse, or large and rapid pulse.</td></tr><tr><td>Reduning injection</td><td>Qing-hao, jin-yin-hua, zhi-zi</td><td>Clinical treatment period&#x02014;severe and critical</td><td>Severe fever and polydipsia, dyspnea and anhelation, delirium, blurred vision, rash, or hematemesis and epistaxis, or convulsion of the limbs. Tongue with little or no fur, deep and count pulse, or large and rapid pulse</td></tr><tr><td>Shenfu injection</td><td>Hong-shen, fu-zi</td><td>Clinical treatment period&#x02014;critical</td><td>Dyspnea, asthma requires assisted ventilation, dizziness, irritability, cold sweaty limbs, purple tongue, thick or dry fur, large floating, and rootless pulse.</td></tr><tr><td>Shengmai injection</td><td>Hong-shen, mai-dong, wu-wei-zi</td><td>Clinical treatment period&#x02014;critical</td><td>Dyspnea, asthma requires assisted ventilation, dizziness, irritability, cold sweaty limbs, purple tongue, thick or dry fur, large floating, and rootless pulse.</td></tr><tr><td>Angongniuhaung-wan</td><td>Niu-huang, she-xiang, zhen-zhu, zhu-sha, xiong-huang, huang-lian, huang-qin, zhi-zi, yu-jin, bing-pian</td><td>Clinical treatment period&#x02014;clinical period 2</td><td>Clearing away heat, detoxifying, calming and resuscitating, fever, pathogen into pericardium, febrile convulsion, delirium, red or crimson tongue, powerful pulse number; apoplexy coma and encephalitis, meningitis, toxic encephalopathy, cerebral hemorrhage, septicemia</td></tr><tr><td>Xiangshaliujun-wan</td><td>Ban-xia, chen-pi, mu-xiang, sha-ren, dang-shen, bai-zhu, fu-ling, jiu-gan-cao</td><td>Clinical treatment period&#x02014;clinical period 3</td><td>Invigorate the spleen and stomach. Used for spleen deficiency and qi stagnation, indigestion, belching Shao, wan abdominal distension and fullness, loose stool, tongue pale moss white greasy</td></tr><tr><td>Tanreqing injection</td><td>Huang-qin, xiong-dan, shan-yang-jiao,-jin-yin-hua, lian-qiao</td><td>Clinical treatment period&#x02014;severe and critical</td><td>Severe fever and polydipsia, dyspnea and anhelation, delirium, blurred vision, rash, or hematemesis and epistaxis, or convulsion of the limbs. Tongue with little or no fur, deep and count pulse, or large and rapid pulse</td></tr><tr><td>Xingnaojing injection</td><td>She-xiang, bing-pian, zhi-zi, yu-jin</td><td>Clinical treatment period&#x02014;severe and critical</td><td>Severe fever and polydipsia, dyspnea and anhelation, delirium, blurred vision, rash, or hematemesis and epistaxis, or convulsion of the limbs. Tongue with little or no fur, deep and count pulse, or large and rapid pulse</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec3"><title>Chemical Medicine</title><sec id="Sec4"><title>Lopinavir/Ritonavir</title><p id="Par8">Lopinavir/ritonavir tablets (trade name: Cleeve) are broad-spectrum antiviral drugs developed by AbbVie Inc., which was first approved by the European Union in 2001 [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. It is a type of human immunodeficiency virus (HIV) protease inhibitor that can block the cleavage of Gag-Pol precursor protein into mature protein, which eventually leads to the production of immature and non-infectious virus particles [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. It has been confirmed that ritonavir is an active peptidomimetic inhibitor against HIV-1 and HIV-2 aspartyl proteases. The enzyme cannot cleave the Gag-Pol precursor protein by inhibiting HIV protease which could lead to the formation of immature forms of HIV particles and prevent a new round of infection [<xref ref-type="bibr" rid="CR47">47</xref>]. Currently, in vitro studies have shown that lopinavir/ritonavir can inhibit the replication of Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV) to exert antiviral effects [<xref ref-type="bibr" rid="CR48">48</xref>]. Based on that, lopinavir/ritonavir has been recommended for the clinical treatment of COVID-19 in China. According to the advantages of lopinavir/ritonavir in antiviral therapy, it is suggested that lopinavir/ritonavir should use in the early period of antiviral treatment to improve clinical symptoms and reduce viral load. The oral dosage is recommended once a day (800&#x000a0;mg/200&#x000a0;mg) that may increase treatment compliance, reduce adverse reactions, control the spread through urine and feces, and hinder the spread of the epidemic [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. However, the latest research has reported that lopinavir/ritonavir treatment did not significantly accelerate clinical improvement, reduce mortality, or diminish throat viral RNA detectability in patients with COVID-19 [<xref ref-type="bibr" rid="CR50">50</xref>]. Besides, it should be noted that lopinavir/ritonavir is an inhibitor of liver P450 isoenzyme CYP3A. When it is combined with drugs that are mainly metabolized by CYP3A, it may lead to increased blood concentration of the combining drugs, which increases the adverse reaction.</p></sec><sec id="Sec5"><title>Ribavirin</title><p id="Par9">Ribavirin is a synthetic nucleoside antiviral drug with broad-spectrum antiviral activity, which inhibits both DNA and RNA viruses and widely used for the treatment of SARS and MERS [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR51">51</xref>&#x02013;<xref ref-type="bibr" rid="CR53">53</xref>]. It was recommended that the combined use of ribavirin and &#x003b1;-interferon or lopinavir, 500&#x000a0;mg/time for adults with 2 to 3 intravenous injections per day, could control and improve patient&#x02019;s condition, but the therapeutic process should be limited to 10&#x000a0;days [<xref ref-type="bibr" rid="CR32">32</xref>]. Notably, patients with contraindications should be excluded before clinical application for the reason that the incidence of adverse reactions of ribavirin is high and the individualized differences are obvious [<xref ref-type="bibr" rid="CR54">54</xref>]. Studies on the effect of ribavirin in vitro showed that ribavirin could reduce viral infection [<xref ref-type="bibr" rid="CR55">55</xref>]. However, the effectiveness and safety of ribavirin for COVID-19 still need further clinical trials to confirm. Medical workers should carefully and comprehensively evaluate the patient&#x02019;s various indicators to ensure the safety of patients&#x02019; medication.</p></sec><sec id="Sec6"><title>Arbidol</title><p id="Par10">Arbidol is a non-nucleoside antiviral drug developed by the research center for pharmaceutical chemistry of the Soviet Union. Arbidol exerts an antiviral effect by inhibiting the fusion of the viral lipid membrane with the host cell to block the replication of the virus [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]. It is active against many enveloped and non-enveloped viruses and has an interferon-inducing effect [<xref ref-type="bibr" rid="CR58">58</xref>]. It has been found that 10&#x02013;30&#x000a0;&#x003bc;mol of arbidol could effectively inhibit SARS-CoV-2 proliferation by 60 times compared with a drug-untreated control group and significantly inhibit the pathological effects of viruses in vitro [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR59">59</xref>].</p></sec><sec id="Sec7"><title>Remdesivir</title><p id="Par11">Remdesivir is a nucleoside drug and an RNA polymerase (RdRp) inhibitor which was developed by Gilead Sciences in the USA [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. Accumulating evidence indicates that remdesivir could inhibit virus replication and play an antiviral role through blocking the synthesis of negative-strand RNA by inhibiting SARS-CoV-2 RdRp, subgenomic mRNA, and subviral genomic RNA [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>]. Remdesivir has shown good anti-MERS-CoV and anti-SARS-CoV activities in vitro and in animal models [<xref ref-type="bibr" rid="CR64">64</xref>] and has anti-SARS-CoV-2 activity in vitro, indicating it could be used as a potential anti-SARS-CoV-2 drug [<xref ref-type="bibr" rid="CR65">65</xref>]. On January 31, 2020, the prestige medical journal &#x0201c;New England Medical Journal&#x0201d; (NEJM) reported the diagnosis and treatment process of the first SARS-CoV-2 infected patient in the USA, showing that remdesivir has a certain role in the treatment [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR66">66</xref>]. Cell research published an article stating that among the six antiviral drugs tested, remdesivir had the strongest inhibitory effect of COVID-19 in vitro (EC<sub>50</sub>&#x02009;=&#x02009;0.77&#x000a0;&#x003bc;mol/L) [<xref ref-type="bibr" rid="CR32">32</xref>]. Currently, remdesivir&#x02019;s clinical trials have been officially launched in China that a total of 761 patients are planned to be included in this study.</p></sec><sec id="Sec8"><title>Favipiravir</title><p id="Par12">Favipiravir is a wide-spectrum nucleoside antiviral drug developed by FUJIFILM Toyama Chemical Co., Ltd. [<xref ref-type="bibr" rid="CR67">67</xref>]. It is a precursor drug that could be metabolized into the active metabolite favipiravir-ribofuranosyl-5&#x02032;-triphosphate (favipiravir-rtp) in vivo, which has an inhibitory effect on the RNA virus RdRp. The drug&#x02019;s initial indication was against influenza [<xref ref-type="bibr" rid="CR68">68</xref>]. But subsequent studies have shown that the drug has inhibitory activity against almost all RNA viruses, such as West Nile virus, yellow fever virus, enterovirus, and Ebola virus [<xref ref-type="bibr" rid="CR69">69</xref>&#x02013;<xref ref-type="bibr" rid="CR72">72</xref>]. On February 15, 2020, favipiravir tablets were marketed in China, and the indication was approved for the treatment of new or recurrent epidemics in adults. Thus, favipiravir became a potential drug for treatment of COVID-19 patients [<xref ref-type="bibr" rid="CR73">73</xref>]. In a small-scale clinical trial of COVID-19, favipiravir has shown promising efficacy and low adverse reactions. It has been shown that favipiravir is effective against SARS-CoV-2 (EC<sub>50</sub>&#x02009;=&#x02009;61.88&#x000a0;&#x003bc;mol/L) [<xref ref-type="bibr" rid="CR32">32</xref>].</p></sec><sec id="Sec9"><title>Darunavir</title><p id="Par13">Darunavir is an inhibitor of protease dimerization and catalytic activity of HIV-1 [<xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR75">75</xref>]. It can selectively inhibit the cleavage of HIV encoded gag-pol precursor protein in virus infected cells, thus blocking the formation of mature infectious virus particles [<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR77">77</xref>]. Clinically, darunavir is mainly used as a drug for AIDS. On February 4, 2020, it was announced that darunavir could significantly inhibit the replication of the virus at concentration of 300&#x000a0;&#x003bc;mol/L [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR54">54</xref>].</p></sec><sec id="Sec10"><title>Emtricitabine and Denofovir Alafenamide</title><p id="Par14">Emtricitabine is a nucleoside reverse transcriptase inhibitor which is used in AIDS treatment [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR79">79</xref>]. It blocks the reverse transcription process of HIV by inhibiting reverse transcriptase and can also effectively inhibit hepatitis B virus (HBV) reverse transcription process [<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR80">80</xref>]. It has been reported that the combination of emtricitabine and denofovir alafenamide in clinical trial for the treatment of COVID-19 was applied with great therapeutic effects [<xref ref-type="bibr" rid="CR32">32</xref>].</p></sec><sec id="Sec11"><title>Chloroquine Phosphate</title><p id="Par15">Chloroquine phosphate is mainly used in the treatment of malaria and rheumatism in clinical [<xref ref-type="bibr" rid="CR81">81</xref>&#x02013;<xref ref-type="bibr" rid="CR83">83</xref>]. Numerous studies have presented that it has broad-spectrum antiviral effect [<xref ref-type="bibr" rid="CR84">84</xref>]. Recently, it has been found that chloroquine phosphate could effectively inhibit the infection of coronavirus at the cellular level [<xref ref-type="bibr" rid="CR85">85</xref>&#x02013;<xref ref-type="bibr" rid="CR87">87</xref>]. It has been recommended for antiviral treatment of the COVID-19 as well [<xref ref-type="bibr" rid="CR88">88</xref>].</p></sec><sec id="Sec12"><title>Hydroxychloroquine</title><p id="Par16">Hydroxychloroquine was developed as an antimalarial drug and has been used for the treatment of rheumatoid arthritis and lupus erythematosus [<xref ref-type="bibr" rid="CR89">89</xref>&#x02013;<xref ref-type="bibr" rid="CR91">91</xref>]. Due to its antiviral activity, hydroxychloroquine has also been used as an adjuvant therapy for AIDS [<xref ref-type="bibr" rid="CR92">92</xref>&#x02013;<xref ref-type="bibr" rid="CR94">94</xref>]. It has been confirmed that hydroxychloroquine also has therapeutic effect against Ebola virus and dengue virus in in vitro studies [<xref ref-type="bibr" rid="CR95">95</xref>]. Recently, it has been reported that some COVID-19 patients benefited from the treatment with hydroxychloroquine [<xref ref-type="bibr" rid="CR96">96</xref>&#x02013;<xref ref-type="bibr" rid="CR99">99</xref>]. Moreover, its effect for virus elimination could be reinforced by azithromycin [<xref ref-type="bibr" rid="CR97">97</xref>].</p></sec></sec><sec id="Sec13"><title>Biological Medicine</title><sec id="Sec14"><title>Interferon &#x003b1;</title><p id="Par17">Interferon (IFN) is a kind of multifunctional cytokine family with broad-spectrum antiviral, antiproliferative, and immunomodulatory activities. According to different binding receptors, it can be divided into type I, type II, and type III. Among them, type II IFN (mainly &#x003b1;/&#x003b2; IFN) plays an important role in the control of virus infection. Naturally, IFN-&#x003b1; is a very important immune protective cytokine in human response to virus infection [<xref ref-type="bibr" rid="CR100">100</xref>, <xref ref-type="bibr" rid="CR101">101</xref>]. It could induce the same cell to produce antiviral protein and limit the further replication and spread of the virus [<xref ref-type="bibr" rid="CR102">102</xref>, <xref ref-type="bibr" rid="CR103">103</xref>]. Moreover, IFN-&#x003b1; has been recommended to be applied in the treatment of COVID-19 recently [<xref ref-type="bibr" rid="CR32">32</xref>].</p></sec><sec id="Sec15"><title>Tocilizumab Injection</title><p id="Par18">Tocilizumab injection is a recombinant humanized monoclonal antibody against human IL-6 receptor, which specifically binds to soluble and membranous IL-6 receptor to block signal transduction, thus inhibiting the activity of IL-6 receptor and achieving the goal of treating rheumatoid arthritis [<xref ref-type="bibr" rid="CR104">104</xref>&#x02013;<xref ref-type="bibr" rid="CR106">106</xref>]. IL-6R plays an important role in the occurrence and development of some inflammatory and autoimmune diseases. As an activator of IL-6, sIL-6R can enhance the sensitivity of cells to IL-6 [<xref ref-type="bibr" rid="CR107">107</xref>]. It has been found that as an antagonist of cytokine interleukin-6 (IL-6), tocilizumab injection is likely to block cytokine storm and thus prevent COVID-19 patients from turning to severe and critical diseases [<xref ref-type="bibr" rid="CR108">108</xref>]. Tocilizumab injection has been recommended as a treatment for COVID-19 by researchers at University of Science and Technology of China.</p></sec><sec id="Sec16"><title>Glucocorticoids</title><p id="Par19">Glucocorticoid is an extremely important regulatory molecule in the human body [<xref ref-type="bibr" rid="CR109">109</xref>]. It plays an important role in regulating the body&#x02019;s development, growth, metabolism, and immune function. It is the most important regulatory hormone in the body&#x02019;s stress response, and it is also the most widely used and effective antiinflammatory and immunosuppressive agent in clinical practice [<xref ref-type="bibr" rid="CR110">110</xref>, <xref ref-type="bibr" rid="CR111">111</xref>]. During the treatment of COVID-19, it is recommended to be used for severe cases with high inflammatory response or children with acute respiratory distress syndrome [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR112">112</xref>]. However, the side effects of glucocorticoids are severe; WHO recommends that glucocorticoids are not suitable for the routine treatment of COVID-19 except in clinical trials [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR113">113</xref>, <xref ref-type="bibr" rid="CR114">114</xref>].</p></sec><sec id="Sec17"><title>Convalescent Plasma Therapy</title><p id="Par20">Currently, the convalescent plasma therapy has been in the process of promotion; some patients&#x02019; clinical indicators and symptoms have been improved [<xref ref-type="bibr" rid="CR32">32</xref>]. There have been a large number of people who have recovered from coronavirus infection, donating valuable serum containing immunoglobulin which seems better than trying to produce large amounts of monoclonal antibodies in the laboratory. However, using antibodies to treat COVID-19 has some obvious problems such as limited sources of therapeutic plasma, different concentrations and activities of antibodies in human plasma of various sources, and non-neutralizing antibodies in plasma that may contribute to cytokine storms and other safety risks. Therefore, the convalescent plasma therapy is only used on a small scale, while large-scale use still needs to wait until we understand the clinical application effect and adverse reactions. The safety and efficacy of convalescent plasma transfusion in SARS-CoV-2-infected patients should be studied within the context of a well-designed clinical trial. In the absence of vaccines and specific therapeutic drugs, the recovery plasma therapy is still an exploratory treatment. The current diagnosis and treatment scheme is recommended to try in severe patients and closely monitor the possible risks [<xref ref-type="bibr" rid="CR115">115</xref>].</p></sec><sec id="Sec18"><title>Other Biological Medicine</title><p id="Par21">There are also other biological medicines on COVID-19 such as human immunoglobulin and intestinal microecological regulator. Some researchers in China have suggested that human immunoglobulins can be selectively used to treat critically patients. Intravenous immunoglobulin in large doses could be used for severe systemic inflammatory response syndrome [<xref ref-type="bibr" rid="CR11">11</xref>]. It has been suggested that intestinal microecological regulator could maintain intestinal microecological balance and prevent secondary bacterial infection [<xref ref-type="bibr" rid="CR32">32</xref>].</p></sec></sec><sec id="Sec19"><title>Perspective</title><p id="Par22">As for a new emerging acute infectious disease caused by SARS-CoV-2, there are still no specific antiviral drugs. All options for its prevention and treatment are based on previous experience in the treatment of SARS, MERS, or other new influenza viruses. Active treatment based on the patient&#x02019;s symptoms is still the main direction of treatment. Up to now, China has made a great breakthrough in fighting against COVID-19, but the situation outside China is not optimistic. The Chinese Health Commission has established several versions of diagnosis and treatment plans on COVID-19, which was formulated in a short time by professionals in various fields. But it is just a temporary solution at present. Since these drugs were not developed for the treatment of COVID-19, the clinical therapeutic effect is surely limited. Besides, the efficacy and safety of involved medicines still need to be confirmed in further clinical treatment and research. Even though those medicines we used have certain therapeutic effect, it is still urgent for medical researchers to carry on the research and development of specific medicine and vaccine according to the infection mechanism and characteristic structure of new crown virus. What is more, an effective mechanism for drug development of coronavirus should be established.</p><p id="Par23">Currently, the enthusiasm for COVID-19 drug research runs high, but whether long-term scientific research can persist after the epidemic is a bit more in doubt. The isolation and structure analysis of various coronaviruses have been completed in early period, but there is still no specific drug for each coronavirus in the world. The reasons are as follows: firstly, the replication mutation rate of the virus is very high, and it is easy to produce drug-resistant strains. Secondly, after the acute infectious period of a novel coronavirus, the patient is likely to have developed a corresponding durable immunity. However, compared with the transient infection of virus epidemic, the new drug development cycle is fairly a long time, which is not suitable for the development of coronavirus drugs economically. Therefore, the joint efforts of government departments and drug research and development departments are needed to achieve a breakthrough in a short period of time, for accumulating experience of the possible future coronavirus epidemic.</p></sec><sec id="Sec20"><title>Conclusions</title><p id="Par24">The drugs used for COVID-19 treatment in China based on the emerging basic and clinical data were summarized above. Among them, Chinese medicines have received broad adoption, especially in treating cases of mild symptoms. There is still a lot for us to do in the face of COVID-19. It is hoped that this review will be useful to provide guidance for the prevention and control of COVID-19.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="funding-information"><title>Funding Information</title><p>This work was supported by the Scientific Research Project of National Natural Science Foundation of China (Nos. 81872979 and 81973439).</p></notes><notes><title>Compliance with Ethical Standards</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of Interest</title><p id="Par25">The authors declare no conflicts of interest relevant to this manuscript.</p></notes><notes id="FPar2"><title>Human and Animal Rights and Informed Consent</title><p id="Par26">This article does not contain any studies with human or animal subjects performed by any of the authors.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ksiazek</surname><given-names>TG</given-names></name><name><surname>Erdman</surname><given-names>D</given-names></name><name><surname>Goldsmith</surname><given-names>CS</given-names></name><name><surname>Zaki</surname><given-names>SR</given-names></name><name><surname>Peret</surname><given-names>T</given-names></name><name><surname>Emery</surname><given-names>S</given-names></name><name><surname>Tong</surname><given-names>S</given-names></name><name><surname>Urbani</surname><given-names>C</given-names></name><name><surname>Comer</surname><given-names>JA</given-names></name><name><surname>Lim</surname><given-names>W</given-names></name><name><surname>Rollin</surname><given-names>PE</given-names></name><name><surname>Dowell</surname><given-names>SF</given-names></name><name><surname>Ling</surname><given-names>AE</given-names></name><name><surname>Humphrey</surname><given-names>CD</given-names></name><name><surname>Shieh</surname><given-names>WJ</given-names></name><name><surname>Guarner</surname><given-names>J</given-names></name><name><surname>Paddock</surname><given-names>CD</given-names></name><name><surname>Rota</surname><given-names>P</given-names></name><name><surname>Fields</surname><given-names>B</given-names></name><name><surname>DeRisi</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>JY</given-names></name><name><surname>Cox</surname><given-names>N</given-names></name><name><surname>Hughes</surname><given-names>JM</given-names></name><name><surname>LeDuc</surname><given-names>JW</given-names></name><name><surname>Bellini</surname><given-names>WJ</given-names></name><name><surname>Anderson</surname><given-names>LJ</given-names></name></person-group><article-title>A novel coronavirus associated with severe acute respiratory syndrome</article-title><source>N Engl J Med</source><year>2003</year><volume>348</volume><issue>20</issue><fpage>1953</fpage><lpage>1966</lpage><?supplied-pmid 12690092?><pub-id pub-id-type="pmid">12690092</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Stratton</surname><given-names>CW</given-names></name><name><surname>Tang</surname><given-names>YW</given-names></name></person-group><article-title>Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle</article-title><source>J Med Virol</source><year>2020</year><volume>92</volume><issue>4</issue><fpage>401</fpage><lpage>402</lpage><?supplied-pmid 7166628?><pub-id pub-id-type="pmid">31950516</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Lu</surname><given-names>R</given-names></name><name><surname>Niu</surname><given-names>P</given-names></name><name><surname>Zhan</surname><given-names>F</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Gao</surname><given-names>GF</given-names></name><name><surname>Tan</surname><given-names>W</given-names></name></person-group><article-title>A novel coronavirus from patients with pneumonia in China, 2019</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><issue>8</issue><fpage>727</fpage><lpage>733</lpage><?supplied-pmid 31978945?><pub-id pub-id-type="pmid">31978945</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bastola</surname><given-names>A</given-names></name><name><surname>Sah</surname><given-names>R</given-names></name><name><surname>Rodriguez-Morales</surname><given-names>AJ</given-names></name><name><surname>Lal</surname><given-names>BK</given-names></name><name><surname>Jha</surname><given-names>R</given-names></name><name><surname>Ojha</surname><given-names>HC</given-names></name><name><surname>Shrestha</surname><given-names>B</given-names></name><name><surname>Chu</surname><given-names>DKW</given-names></name><name><surname>Poon</surname><given-names>LLM</given-names></name><name><surname>Costello</surname><given-names>A</given-names></name><name><surname>Morita</surname><given-names>K</given-names></name><name><surname>Pandey</surname><given-names>BD</given-names></name></person-group><article-title>The first 2019 novel coronavirus case in Nepal</article-title><source>Lancet Infect Dis</source><year>2020</year><volume>20</volume><issue>3</issue><fpage>279</fpage><lpage>280</lpage><?supplied-pmid 32057299?><pub-id pub-id-type="pmid">32057299</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holshue</surname><given-names>ML</given-names></name><name><surname>DeBolt</surname><given-names>C</given-names></name><name><surname>Lindquist</surname><given-names>S</given-names></name><name><surname>Lofy</surname><given-names>KH</given-names></name><name><surname>Wiesman</surname><given-names>J</given-names></name><name><surname>Bruce</surname><given-names>H</given-names></name><name><surname>Spitters</surname><given-names>C</given-names></name><name><surname>Ericson</surname><given-names>K</given-names></name><name><surname>Wilkerson</surname><given-names>S</given-names></name><name><surname>Tural</surname><given-names>A</given-names></name><name><surname>Diaz</surname><given-names>G</given-names></name><name><surname>Cohn</surname><given-names>A</given-names></name><name><surname>Fox</surname><given-names>L</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Gerber</surname><given-names>SI</given-names></name><name><surname>Kim</surname><given-names>L</given-names></name><name><surname>Tong</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Lindstrom</surname><given-names>S</given-names></name><name><surname>Pallansch</surname><given-names>MA</given-names></name><name><surname>Weldon</surname><given-names>WC</given-names></name><name><surname>Biggs</surname><given-names>HM</given-names></name><name><surname>Uyeki</surname><given-names>TM</given-names></name><name><surname>Pillai</surname><given-names>SK</given-names></name></person-group><article-title>First case of 2019 novel coronavirus in the United States</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><issue>10</issue><fpage>929</fpage><lpage>936</lpage><?supplied-pmid 32004427?><pub-id pub-id-type="pmid">32004427</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livingston</surname><given-names>E</given-names></name><name><surname>Bucher</surname><given-names>K</given-names></name></person-group><article-title>Coronavirus disease 2019 (COVID-19) in Italy</article-title><source>Jama</source><year>2020</year><volume>323</volume><fpage>1335</fpage></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>CC</given-names></name><name><surname>Shih</surname><given-names>TP</given-names></name><name><surname>Ko</surname><given-names>WC</given-names></name><name><surname>Tang</surname><given-names>HJ</given-names></name><name><surname>Hsueh</surname><given-names>PR</given-names></name></person-group><article-title>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges</article-title><source>Int J Antimicrob Agents</source><year>2020</year><volume>55</volume><issue>3</issue><fpage>105924</fpage><?supplied-pmid 32081636?><pub-id pub-id-type="pmid">32081636</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>YR</given-names></name><name><surname>Cao</surname><given-names>QD</given-names></name><name><surname>Hong</surname><given-names>ZS</given-names></name><name><surname>Tan</surname><given-names>YY</given-names></name><name><surname>Chen</surname><given-names>SD</given-names></name><name><surname>Jin</surname><given-names>HJ</given-names></name><name><surname>Tan</surname><given-names>KS</given-names></name><name><surname>Wang</surname><given-names>DY</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name></person-group><article-title>The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status</article-title><source>Mil Med Res</source><year>2020</year><volume>7</volume><issue>1</issue><fpage>11</fpage><?supplied-pmid 32169119?><pub-id pub-id-type="pmid">32169119</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salzberger</surname><given-names>B</given-names></name><name><surname>Gl&#x000fc;ck</surname><given-names>T</given-names></name><name><surname>Ehrenstein</surname><given-names>B</given-names></name></person-group><article-title>Successful containment of COVID-19: the WHO-report on the COVID-19 outbreak in China</article-title><source>Infection</source><year>2020</year><volume>48</volume><issue>2</issue><fpage>151</fpage><lpage>153</lpage><pub-id pub-id-type="pmid">32185635</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silverstein</surname><given-names>WK</given-names></name><name><surname>Stroud</surname><given-names>L</given-names></name><name><surname>Cleghorn</surname><given-names>GE</given-names></name><name><surname>Leis</surname><given-names>JA</given-names></name></person-group><article-title>First imported case of 2019 novel coronavirus in Canada, presenting as mild pneumonia</article-title><source>Lancet</source><year>2020</year><volume>395</volume><issue>(10225)</issue><fpage>734</fpage><?supplied-pmid 32061312?><pub-id pub-id-type="pmid">32061312</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Wang D; Hu B; Hu C; Zhu F; Liu X; Zhang J; Wang B; Xiang H; Cheng Z; Xiong Y; Zhao Y; Li Y; Wang X; Peng Z Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. Jama 2020<bold>.</bold></mixed-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>N</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Qu</surname><given-names>J</given-names></name><name><surname>Gong</surname><given-names>F</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Qiu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study</article-title><source>Lancet</source><year>2020</year><volume>395</volume><issue>10223</issue><fpage>507</fpage><lpage>513</lpage><?supplied-pmid 7135076?><pub-id pub-id-type="pmid">32007143</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Henry BM; Vikse J Clinical characteristics of Covid-19 in China. N Engl J Med 2020<bold>,</bold> 382.</mixed-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Tai</surname><given-names>Y</given-names></name><name><surname>Bai</surname><given-names>C</given-names></name><name><surname>Gao</surname><given-names>T</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Xia</surname><given-names>P</given-names></name><name><surname>Dong</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>FS</given-names></name></person-group><article-title>Pathological findings of COVID-19 associated with acute respiratory distress syndrome</article-title><source>Lancet Respir Med</source><year>2020</year><volume>8</volume><fpage>420</fpage><lpage>422</lpage><?supplied-pmid 32085846?><pub-id pub-id-type="pmid">32085846</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Wunderink</surname><given-names>RG</given-names></name></person-group><article-title>MERS, SARS and other coronaviruses as causes of pneumonia</article-title><source>Respirology</source><year>2018</year><volume>23</volume><issue>2</issue><fpage>130</fpage><lpage>137</lpage><?supplied-pmid 29052924?><pub-id pub-id-type="pmid">29052924</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">Liu Y; Gayle AA; Wilder-Smith A; Rockl&#x000f6;v J The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med 2020<bold>,</bold> 27, (2).</mixed-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>JF</given-names></name><name><surname>Yuan</surname><given-names>S</given-names></name><name><surname>Kok</surname><given-names>KH</given-names></name><collab>To, K. K</collab><name><surname>Chu</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Xing</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Yip</surname><given-names>CC</given-names></name><name><surname>Poon</surname><given-names>RW</given-names></name><name><surname>Tsoi</surname><given-names>HW</given-names></name><name><surname>Lo</surname><given-names>SK</given-names></name><name><surname>Chan</surname><given-names>KH</given-names></name><name><surname>Poon</surname><given-names>VK</given-names></name><name><surname>Chan</surname><given-names>WM</given-names></name><name><surname>Ip</surname><given-names>JD</given-names></name><name><surname>Cai</surname><given-names>JP</given-names></name><name><surname>Cheng</surname><given-names>VC</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Hui</surname><given-names>CK</given-names></name><name><surname>Yuen</surname><given-names>KY</given-names></name></person-group><article-title>A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster</article-title><source>Lancet</source><year>2020</year><volume>395</volume><issue>10223</issue><fpage>514</fpage><lpage>523</lpage><?supplied-pmid 31986261?><pub-id pub-id-type="pmid">31986261</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phan</surname><given-names>LT</given-names></name><name><surname>Nguyen</surname><given-names>TV</given-names></name><name><surname>Luong</surname><given-names>QC</given-names></name><name><surname>Nguyen</surname><given-names>TV</given-names></name><name><surname>Nguyen</surname><given-names>HT</given-names></name><name><surname>Le</surname><given-names>HQ</given-names></name><name><surname>Nguyen</surname><given-names>TT</given-names></name><name><surname>Cao</surname><given-names>TM</given-names></name><name><surname>Pham</surname><given-names>QD</given-names></name></person-group><article-title>Importation and human-to-human transmission of a novel coronavirus in Vietnam</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><issue>9</issue><fpage>872</fpage><lpage>874</lpage><?supplied-pmid 31991079?><pub-id pub-id-type="pmid">31991079</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Guan</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Tong</surname><given-names>Y</given-names></name><name><surname>Ren</surname><given-names>R</given-names></name><name><surname>Leung</surname><given-names>KSM</given-names></name><name><surname>Lau</surname><given-names>EHY</given-names></name><name><surname>Wong</surname><given-names>JY</given-names></name><name><surname>Xing</surname><given-names>X</given-names></name><name><surname>Xiang</surname><given-names>N</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Tu</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Shao</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Tao</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Deng</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>G</given-names></name><name><surname>Lam</surname><given-names>TTY</given-names></name><name><surname>Wu</surname><given-names>JT</given-names></name><name><surname>Gao</surname><given-names>GF</given-names></name><name><surname>Cowling</surname><given-names>BJ</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Leung</surname><given-names>GM</given-names></name><name><surname>Feng</surname><given-names>Z</given-names></name></person-group><article-title>Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><issue>13</issue><fpage>1199</fpage><lpage>1207</lpage><?supplied-pmid 31995857?><pub-id pub-id-type="pmid">31995857</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuen</surname><given-names>KS</given-names></name><name><surname>Ye</surname><given-names>ZW</given-names></name><name><surname>Fung</surname><given-names>SY</given-names></name><name><surname>Chan</surname><given-names>CP</given-names></name><name><surname>Jin</surname><given-names>DY</given-names></name></person-group><article-title>SARS-CoV-2 and COVID-19: the most important research questions</article-title><source>Cell Biosci</source><year>2020</year><volume>10</volume><fpage>40</fpage><?supplied-pmid 32190290?><pub-id pub-id-type="pmid">32190290</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Jernigan</surname><given-names>DB</given-names></name></person-group><article-title>Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel coronavirus outbreak - United States, December 31, 2019-February 4, 2020</article-title><source>MMWR Morb Mortal Wkly Rep</source><year>2020</year><volume>69</volume><issue>5</issue><fpage>140</fpage><lpage>146</lpage><?supplied-pmid 32027631?><pub-id pub-id-type="pmid">32027631</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baden</surname><given-names>LR</given-names></name><name><surname>Rubin</surname><given-names>EJ</given-names></name></person-group><article-title>Covid-19 - the search for effective therapy</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><fpage>1851</fpage><lpage>1852</lpage><?supplied-pmid 32187463?><pub-id pub-id-type="pmid">32187463</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kupferschmidt</surname><given-names>K</given-names></name><name><surname>Cohen</surname><given-names>J</given-names></name></person-group><article-title>Race to find COVID-19 treatments accelerates</article-title><source>Science</source><year>2020</year><volume>367</volume><issue>6485</issue><fpage>1412</fpage><lpage>1413</lpage><?supplied-pmid 32217705?><pub-id pub-id-type="pmid">32217705</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>AC</given-names></name><name><surname>Goh</surname><given-names>HP</given-names></name><name><surname>Koh</surname><given-names>D</given-names></name></person-group><article-title>Treatment of COVID-19: old tricks for new challenges</article-title><source>Crit Care</source><year>2020</year><volume>24</volume><issue>1</issue><fpage>91</fpage><?supplied-pmid 32178711?><pub-id pub-id-type="pmid">32178711</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>H</given-names></name></person-group><article-title>Drug treatment options for the 2019-new coronavirus (2019-nCoV)</article-title><source>Biosci Trends</source><year>2020</year><volume>14</volume><issue>1</issue><fpage>69</fpage><lpage>71</lpage><?supplied-pmid 31996494?><pub-id pub-id-type="pmid">31996494</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">Raoult D; Hsueh PR; Stefani S; Rolain JM, COVID-19 therapeutic and prevention. Int J Antimicrob Agents 2020, 105937.</mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Wu J; Li W; Shi X; Chen Z; Jiang B; Liu J; Wang D.; Liu C; Meng Y; Cui L; Yu J; Cao H; Li L, Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). J Intern Med 2020.</mixed-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitj&#x000e0;</surname><given-names>O</given-names></name><name><surname>Clotet</surname><given-names>B</given-names></name></person-group><article-title>Use of antiviral drugs to reduce COVID-19 transmission</article-title><source>Lancet Glob Health</source><year>2020</year><volume>8</volume><fpage>e639</fpage><lpage>e640</lpage><?supplied-pmid 32199468?><pub-id pub-id-type="pmid">32199468</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>SF</given-names></name><name><surname>Ho</surname><given-names>YC</given-names></name></person-group><article-title>SARS-CoV-2: a storm is raging</article-title><source>J Clin Invest</source><year>2020</year><volume>130</volume><fpage>2202</fpage><lpage>2205</lpage><?supplied-pmid 32217834?><pub-id pub-id-type="pmid">32217834</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>JL</given-names></name><name><surname>Zhang</surname><given-names>AH</given-names></name><name><surname>Wang</surname><given-names>XJ</given-names></name></person-group><article-title>Traditional Chinese medicine for COVID-19 treatment</article-title><source>Pharmacol Res</source><year>2020</year><volume>155</volume><fpage>104743</fpage><?supplied-pmid 32145402?><pub-id pub-id-type="pmid">32145402</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Guidance for corona virus disease 2019: prevention, control, diagnosis and management. 2020, (People's Medical Publishing House), 146.</mixed-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">Chan KW, Wong VT, Tang SCW. COVID-19: an update on the epidemiological, clinical, preventive and therapeutic evidence and guidelines of integrative Chinese-Western medicine for the management of 2019 novel coronavirus disease. Am J Chin Med. 2020:1&#x02013;26.</mixed-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">Luo H, Tang QL, Shang YX, Liang SB, Yang M, Robinson N, et al. Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs. Chin J Integr Med. 2020:1&#x02013;8.</mixed-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Wan S; Xiang Y; Fang W; Zheng Y; Li B; Hu Y; Lang C; Huang D; Sun Q; Xiong Y; Huang X; Lv J; Luo Y; Shen L; Yang H; Huang G; Yang R, Clinical features and treatment of COVID-19 patients in Northeast Chongqing. J Med Virol 2020.</mixed-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name></person-group><article-title>Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment</article-title><source>Biosci Trends</source><year>2020</year><volume>14</volume><issue>1</issue><fpage>64</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">32037389</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Runfeng L; Yunlong H; Jicheng H; Weiqi P; Qinhai M; Yongxia S; Chufang L; Jin Z; Zhenhua J; Haiming J; Kui Z; Shuxiang H; Jun D; Xiaobo L; Xiaotao H; Lin W; Nanshan Z; Zifeng Y, Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res 2020, 104761.</mixed-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Guan</surname><given-names>W</given-names></name><name><surname>Ma</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>ZF</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title>Efficacy and safety of Chou-Ling-Dan granules in the treatment of seasonal influenza via combining Western and traditional Chinese medicine: protocol for a multicentre, randomised controlled clinical trial</article-title><source>BMJ Open</source><year>2019</year><volume>9</volume><issue>4</issue><fpage>e024800</fpage><?supplied-pmid 30944133?><pub-id pub-id-type="pmid">30944133</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other">Ma Q; Yu Q; Xing X; Liu S; Shi C; Luo J, San Wu Huangqin Decoction, a Chinese herbal formula, inhibits influenza a/PR/8/34 (H1N1) virus infection in vitro and in vivo. Viruses 2018<bold>,</bold> 10, (3).</mixed-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Yan</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>Chinese herbal medicine compound Yi-Zhi-Hao pellet inhibits replication of influenza virus infection through activation of heme oxygenase-1</article-title><source>Acta Pharm Sin B</source><year>2017</year><volume>7</volume><issue>6</issue><fpage>630</fpage><lpage>637</lpage><?supplied-pmid 29159022?><pub-id pub-id-type="pmid">29159022</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name></person-group><article-title>Effect of traditional Chinese medicine for treating human immunodeficiency virus infections and acquired immune deficiency syndrome: boosting immune and alleviating symptoms</article-title><source>Chin J Integr Med</source><year>2016</year><volume>22</volume><issue>1</issue><fpage>3</fpage><lpage>8</lpage><?supplied-pmid 26577109?><pub-id pub-id-type="pmid">26577109</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Yuan</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name></person-group><article-title>The antiviral and antimicrobial activities of licorice, a widely-used Chinese herb</article-title><source>Acta Pharm Sin B</source><year>2015</year><volume>5</volume><issue>4</issue><fpage>310</fpage><lpage>315</lpage><?supplied-pmid 26579460?><pub-id pub-id-type="pmid">26579460</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>YJ</given-names></name><name><surname>Yen</surname><given-names>MH</given-names></name><name><surname>Chiang</surname><given-names>YW</given-names></name><name><surname>Yeh</surname><given-names>CF</given-names></name><name><surname>Chiang</surname><given-names>LC</given-names></name><name><surname>Shieh</surname><given-names>DE</given-names></name><name><surname>Yeh</surname><given-names>I</given-names></name><name><surname>Chang</surname><given-names>JS</given-names></name></person-group><article-title>Gan-Lu-Siao-Du-yin, a prescription of traditional Chinese medicine, inhibited enterovirus 71 replication, translation, and virus-induced cell apoptosis</article-title><source>J Ethnopharmacol</source><year>2016</year><volume>185</volume><fpage>132</fpage><lpage>139</lpage><?supplied-pmid 26993050?><pub-id pub-id-type="pmid">26993050</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Totura</surname><given-names>AL</given-names></name><name><surname>Bavari</surname><given-names>S</given-names></name></person-group><article-title>Broad-spectrum coronavirus antiviral drug discovery</article-title><source>Expert Opin Drug Discovery</source><year>2019</year><volume>14</volume><issue>4</issue><fpage>397</fpage><lpage>412</lpage></element-citation></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="other">Lopinavir. In LiverTox: clinical and research information on drug-induced liver injury, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda (MD), 2012.</mixed-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canals</surname><given-names>F</given-names></name><name><surname>Masi&#x000e1;</surname><given-names>M</given-names></name><name><surname>Guti&#x000e9;rrez</surname><given-names>F</given-names></name></person-group><article-title>Developments in early diagnosis and therapy of HIV infection in newborns</article-title><source>Expert Opin Pharmacother</source><year>2018</year><volume>19</volume><issue>1</issue><fpage>13</fpage><lpage>25</lpage><?supplied-pmid 28764578?><pub-id pub-id-type="pmid">28764578</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="other">Coelho AV; Tricarico PM; Celsi F; Crovella S, Antiretroviral treatment in HIV-1-positive mothers: neurological implications in virus-free children. Int J Mol Sci 2017<bold>,</bold> 18, (2).</mixed-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barlow-Mosha</surname><given-names>L</given-names></name><name><surname>Angelidou</surname><given-names>K</given-names></name><name><surname>Lindsey</surname><given-names>J</given-names></name><name><surname>Archary</surname><given-names>M</given-names></name><name><surname>Cotton</surname><given-names>M</given-names></name><name><surname>Dittmer</surname><given-names>S</given-names></name><name><surname>Fairlie</surname><given-names>L</given-names></name><name><surname>Kabugho</surname><given-names>E</given-names></name><name><surname>Kamthunzi</surname><given-names>P</given-names></name><name><surname>Kinikar</surname><given-names>A</given-names></name><name><surname>Mbengeranwa</surname><given-names>T</given-names></name><name><surname>Msuya</surname><given-names>L</given-names></name><name><surname>Sambo</surname><given-names>P</given-names></name><name><surname>Patel</surname><given-names>K</given-names></name><name><surname>Barr</surname><given-names>E</given-names></name><name><surname>Jean-Phillipe</surname><given-names>P</given-names></name><name><surname>Violari</surname><given-names>A</given-names></name><name><surname>Mofenson</surname><given-names>L</given-names></name><name><surname>Palumbo</surname><given-names>P</given-names></name><name><surname>Chi</surname><given-names>BH</given-names></name></person-group><article-title>Nevirapine- versus lopinavir/ritonavir-based antiretroviral therapy in HIV-infected infants and young children: long-term follow-up of the IMPAACT P1060 randomized trial</article-title><source>Clin Infect Dis</source><year>2016</year><volume>63</volume><issue>8</issue><fpage>1113</fpage><lpage>1121</lpage><?supplied-pmid 27439527?><pub-id pub-id-type="pmid">27439527</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mo</surname><given-names>Y</given-names></name><name><surname>Fisher</surname><given-names>D</given-names></name></person-group><article-title>A review of treatment modalities for Middle East respiratory syndrome</article-title><source>J Antimicrob Chemother</source><year>2016</year><volume>71</volume><issue>12</issue><fpage>3340</fpage><lpage>3350</lpage><?supplied-pmid 27585965?><pub-id pub-id-type="pmid">27585965</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><mixed-citation publication-type="other">Martinez MA, Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother 2020<bold>, 64</bold>.</mixed-citation></ref><ref id="CR50"><label>50.</label><mixed-citation publication-type="other">Cao, B.; Wang, Y.; Wen, D.; Liu, W.; Wang, J.; Fan, G.; Ruan, L.; Song, B.; Cai, Y.; Wei, M.; Li, X.; Xia, J.; Chen, N.; Xiang, J.; Yu, T.; Bai, T.; Xie, X.; Zhang, L.; Li, C.; Yuan, Y.; Chen, H.; Li, H.; Huang, H.; Tu, S.; Gong, F.; Liu, Y.; Wei, Y.; Dong, C.; Zhou, F.; Gu, X.; Xu, J.; Liu, Z.; Zhang, Y.; Li, H.; Shang, L.; Wang, K.; Li, K.; Zhou, X.; Dong, X.; Qu, Z.; Lu, S.; Hu, X.; Ruan, S.; Luo, S.; Wu, J.; Peng, L.; Cheng, F.; Pan, L.; Zou, J.; Jia, C.; Wang, J.; Liu, X.; Wang, S.; Wu, X.; Ge, Q.; He, J.; Zhan, H.; Qiu, F.; Guo, L.; Huang, C.; Jaki, T.; Hayden, F. G.; Horby, P. W.; Zhang, D.; Wang, C., A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020.</mixed-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jordan</surname><given-names>PC</given-names></name><name><surname>Stevens</surname><given-names>SK</given-names></name><name><surname>Deval</surname><given-names>J</given-names></name></person-group><article-title>Nucleosides for the treatment of respiratory RNA virus infections</article-title><source>Antivir Chem Chemother</source><year>2018</year><volume>26</volume><fpage>2040206618764483</fpage><?supplied-pmid 29562753?><pub-id pub-id-type="pmid">29562753</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabaan</surname><given-names>AA</given-names></name><name><surname>Alahmed</surname><given-names>SH</given-names></name><name><surname>Bazzi</surname><given-names>AM</given-names></name><name><surname>Alhani</surname><given-names>HM</given-names></name></person-group><article-title>A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective</article-title><source>J Med Microbiol</source><year>2017</year><volume>66</volume><issue>9</issue><fpage>1261</fpage><lpage>1274</lpage><?supplied-pmid 28855003?><pub-id pub-id-type="pmid">28855003</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Tawfiq</surname><given-names>JA</given-names></name><name><surname>Memish</surname><given-names>ZA</given-names></name></person-group><article-title>Update on therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)</article-title><source>Expert Rev Anti-Infect Ther</source><year>2017</year><volume>15</volume><issue>3</issue><fpage>269</fpage><lpage>275</lpage><?supplied-pmid 27937060?><pub-id pub-id-type="pmid">27937060</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><mixed-citation publication-type="other">Zhang C, Huang S, Zheng F, Dai Y. Controversial treatments: an updated understanding of the coronavirus disease. J Med Virol. 2019:2020.</mixed-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feld</surname><given-names>JJ</given-names></name><name><surname>Bernstein</surname><given-names>DE</given-names></name><name><surname>Younes</surname><given-names>Z</given-names></name><name><surname>Vlierberghe</surname><given-names>HV</given-names></name><name><surname>Larsen</surname><given-names>L</given-names></name><name><surname>Tatsch</surname><given-names>F</given-names></name><name><surname>Ferenci</surname><given-names>P</given-names></name></person-group><article-title>Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin</article-title><source>Liver Int</source><year>2018</year><volume>38</volume><issue>9</issue><fpage>1571</fpage><lpage>1575</lpage><?supplied-pmid 29377566?><pub-id pub-id-type="pmid">29377566</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blaising</surname><given-names>J</given-names></name><name><surname>Polyak</surname><given-names>SJ</given-names></name><name><surname>P&#x000e9;cheur</surname><given-names>EI</given-names></name></person-group><article-title>Arbidol as a broad-spectrum antiviral: an update</article-title><source>Antivir Res</source><year>2014</year><volume>107</volume><fpage>84</fpage><lpage>94</lpage><?supplied-pmid 24769245?><pub-id pub-id-type="pmid">24769245</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdelnabi</surname><given-names>R</given-names></name><name><surname>Neyts</surname><given-names>J</given-names></name><name><surname>Delang</surname><given-names>L</given-names></name></person-group><article-title>Towards antivirals against chikungunya virus</article-title><source>Antivir Res</source><year>2015</year><volume>121</volume><fpage>59</fpage><lpage>68</lpage><?supplied-pmid 26119058?><pub-id pub-id-type="pmid">26119058</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teissier</surname><given-names>E</given-names></name><name><surname>Penin</surname><given-names>F</given-names></name><name><surname>P&#x000e9;cheur</surname><given-names>EI</given-names></name></person-group><article-title>Targeting cell entry of enveloped viruses as an antiviral strategy</article-title><source>Molecules</source><year>2010</year><volume>16</volume><issue>1</issue><fpage>221</fpage><lpage>250</lpage><?supplied-pmid 21193846?><pub-id pub-id-type="pmid">21193846</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><mixed-citation publication-type="other">Deng L; Li C; Zeng Q; Liu X; Li X; Zhang H; Hong Z; Xia J, Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: a retrospective cohort study. J Inf Secur 2020.</mixed-citation></ref><ref id="CR60"><label>60.</label><mixed-citation publication-type="other">Gordon C J; Tchesnokov EP; Feng JY; Porter DP; Gotte M, The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem 2020.</mixed-citation></ref><ref id="CR61"><label>61.</label><mixed-citation publication-type="other">Tchesnokov EP; Feng JY; Porter DP; G&#x000f6;tte M, Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir. Viruses 2019<bold>,</bold> 11, (4).</mixed-citation></ref><ref id="CR62"><label>62.</label><mixed-citation publication-type="other">Ko WC; Rolain JM; Lee NY; Chen PL; Huang CT; Lee PI; Hsueh PR, Arguments in favour of remdesivir for treating SARS-CoV-2 infections. Int J Antimicrob Agents 2020, 105933.</mixed-citation></ref><ref id="CR63"><label>63.</label><mixed-citation publication-type="other">Al-Tawfiq JA; Al-Homoud AH; Memish ZA, Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis 2020, 101615.</mixed-citation></ref><ref id="CR64"><label>64.</label><mixed-citation publication-type="other">Sheahan, T. P.; Sims, A. C.; Leist, S. R.; Sch&#x000e4;fer, A.; Won, J.; Brown, A. J.; Montgomery, S. A.; Hogg, A.; Babusis, D.; Clarke, M. O.; Spahn, J. E.; Bauer, L.; Sellers, S.; Porter, D.; Feng, J. Y.; Cihlar, T.; Jordan, R.; Denison, M. R.; Baric, R. S., Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. <italic>Nat</italic> Commun 2020, 11, (1), 222.</mixed-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Cao</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>Z</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Zhong</surname><given-names>W</given-names></name><name><surname>Xiao</surname><given-names>G</given-names></name></person-group><article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</article-title><source>Cell Res</source><year>2020</year><volume>30</volume><issue>3</issue><fpage>269</fpage><lpage>271</lpage><?supplied-pmid 7054408?><pub-id pub-id-type="pmid">32020029</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>YM</given-names></name><name><surname>Xu</surname><given-names>JY</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name></person-group><article-title>Potential antiviral therapeutics for 2019 novel coronavirus. Zhonghua</article-title><source>Zhonghua Jie He He Hu Xi Za Zhi</source><year>2020</year><volume>43</volume><issue>0</issue><fpage>E002</fpage><?supplied-pmid 32023685?><pub-id pub-id-type="pmid">32023685</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><mixed-citation publication-type="other">Shiraki K; Daikoku T, Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther 2020, 107512.</mixed-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldhill</surname><given-names>DH</given-names></name><name><surname>Te Velthuis</surname><given-names>AJW</given-names></name><name><surname>Fletcher</surname><given-names>RA</given-names></name><name><surname>Langat</surname><given-names>P</given-names></name><name><surname>Zambon</surname><given-names>M</given-names></name><name><surname>Lackenby</surname><given-names>A</given-names></name><name><surname>Barclay</surname><given-names>WS</given-names></name></person-group><article-title>The mechanism of resistance to favipiravir in influenza</article-title><source>Proc Natl Acad Sci U S A</source><year>2018</year><volume>115</volume><issue>45</issue><fpage>11613</fpage><lpage>11618</lpage><?supplied-pmid 30352857?><pub-id pub-id-type="pmid">30352857</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furuta</surname><given-names>Y</given-names></name><name><surname>Gowen</surname><given-names>BB</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Shiraki</surname><given-names>K</given-names></name><name><surname>Smee</surname><given-names>DF</given-names></name><name><surname>Barnard</surname><given-names>DL</given-names></name></person-group><article-title>Favipiravir (T-705), a novel viral RNA polymerase inhibitor</article-title><source>Antivir Res</source><year>2013</year><volume>100</volume><issue>2</issue><fpage>446</fpage><lpage>454</lpage><?supplied-pmid 24084488?><pub-id pub-id-type="pmid">24084488</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furuta</surname><given-names>Y</given-names></name><name><surname>Komeno</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name></person-group><article-title>Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase</article-title><source>Proc Jpn Acad Ser B Phys Biol Sci</source><year>2017</year><volume>93</volume><issue>7</issue><fpage>449</fpage><lpage>463</lpage><?supplied-pmid 28769016?><pub-id pub-id-type="pmid">28769016</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><mixed-citation publication-type="other">Guedj, J.; Piorkowski, G.; Jacquot, F.; Madelain, V.; Nguyen, T. H. T.; Rodallec, A.; Gunther, S.; Carbonnelle, C.; Mentr&#x000e9;, F.; Raoul, H.; de Lamballerie, X., Antiviral efficacy of favipiravir against Ebola virus: a translational study in cynomolgus macaques. PLoS Med 2018, 15, (3), e1002535.</mixed-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delang</surname><given-names>L</given-names></name><name><surname>Abdelnabi</surname><given-names>R</given-names></name><name><surname>Neyts</surname><given-names>J</given-names></name></person-group><article-title>Favipiravir as a potential countermeasure against neglected and emerging RNA viruses</article-title><source>Antivir Res</source><year>2018</year><volume>153</volume><fpage>85</fpage><lpage>94</lpage><?supplied-pmid 29524445?><pub-id pub-id-type="pmid">29524445</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name></person-group><article-title>Discovering drugs to treat coronavirus disease 2019 (COVID-19)</article-title><source>Drug Discov Ther</source><year>2020</year><volume>14</volume><issue>1</issue><fpage>58</fpage><lpage>60</lpage><?supplied-pmid 32147628?><pub-id pub-id-type="pmid">32147628</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Potard</surname><given-names>V</given-names></name><name><surname>Canestri</surname><given-names>A</given-names></name><name><surname>Gallien</surname><given-names>S</given-names></name><name><surname>Costagliola</surname><given-names>D</given-names></name></person-group><article-title>Use of darunavir in HIV-1-infected individuals in routine clinical practice from 2012 to 2016 in France</article-title><source>J Antimicrob Chemother</source><year>2019</year><volume>74</volume><issue>11</issue><fpage>3305</fpage><lpage>3314</lpage><?supplied-pmid 31384941?><pub-id pub-id-type="pmid">31384941</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spagnuolo</surname><given-names>V</given-names></name><name><surname>Castagna</surname><given-names>A</given-names></name><name><surname>Lazzarin</surname><given-names>A</given-names></name></person-group><article-title>Darunavir for the treatment of HIV infection</article-title><source>Expert Opin Pharmacother</source><year>2018</year><volume>19</volume><issue>10</issue><fpage>1149</fpage><lpage>1163</lpage><?supplied-pmid 29913082?><pub-id pub-id-type="pmid">29913082</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><mixed-citation publication-type="other">Llibre, J. M., Development of darunavir over the entire spectrum of HIV infection. Enferm Infecc Microbiol Clin 2018<bold>,</bold> 36 Suppl 2, 3&#x02013;9.</mixed-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deeks</surname><given-names>ED</given-names></name></person-group><article-title>Darunavir/cobicistat/emtricitabine/tenofovir alafenamide: a review in HIV-1 infection</article-title><source>Drugs</source><year>2018</year><volume>78</volume><issue>10</issue><fpage>1013</fpage><lpage>1024</lpage><?supplied-pmid 29915897?><pub-id pub-id-type="pmid">29915897</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deeks</surname><given-names>ED</given-names></name></person-group><article-title>Bictegravir/emtricitabine/tenofovir alafenamide: a review in HIV-1 infection</article-title><source>Drugs</source><year>2018</year><volume>78</volume><issue>17</issue><fpage>1817</fpage><lpage>1828</lpage><?supplied-pmid 30460547?><pub-id pub-id-type="pmid">30460547</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greig</surname><given-names>SL</given-names></name><name><surname>Deeks</surname><given-names>ED</given-names></name></person-group><article-title>Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide: a review in HIV-1 infection</article-title><source>Drugs</source><year>2016</year><volume>76</volume><issue>9</issue><fpage>957</fpage><lpage>968</lpage><?supplied-pmid 27189707?><pub-id pub-id-type="pmid">27189707</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><mixed-citation publication-type="other">Muller JT; Al Khalili Y, Emtricitabine. In <italic>StatPearls</italic>, StatPearls Publishing. Copyright &#x000a9; 2020, StatPearls Publishing LLC: Treasure Island (FL), 2020.</mixed-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shafi</surname><given-names>H</given-names></name><name><surname>Reddy</surname><given-names>DVS</given-names></name><name><surname>Khan</surname><given-names>T</given-names></name><name><surname>Ranjan</surname><given-names>R</given-names></name><name><surname>Srivastava</surname><given-names>A</given-names></name><name><surname>Vaishya</surname><given-names>S</given-names></name><name><surname>Sharma</surname><given-names>T</given-names></name><name><surname>Siddiqui</surname><given-names>MI</given-names></name><name><surname>Habib</surname><given-names>S</given-names></name><name><surname>Misra</surname><given-names>A</given-names></name></person-group><article-title>Dehydroascorbate-derivatized chitosan particles for targeting antimalarial agents to infected erythrocytes</article-title><source>Int J Pharm</source><year>2017</year><volume>524</volume><issue>1&#x02013;2</issue><fpage>205</fpage><lpage>214</lpage><?supplied-pmid 28377317?><pub-id pub-id-type="pmid">28377317</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukuda</surname><given-names>MM</given-names></name><name><surname>Krudsood</surname><given-names>S</given-names></name><name><surname>Mohamed</surname><given-names>K</given-names></name><name><surname>Green</surname><given-names>JA</given-names></name><name><surname>Warrasak</surname><given-names>S</given-names></name><name><surname>Noedl</surname><given-names>H</given-names></name><name><surname>Euswas</surname><given-names>A</given-names></name><name><surname>Ittiverakul</surname><given-names>M</given-names></name><name><surname>Buathong</surname><given-names>N</given-names></name><name><surname>Sriwichai</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>RS</given-names></name><name><surname>Ohrt</surname><given-names>C</given-names></name></person-group><article-title>A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria</article-title><source>PLoS One</source><year>2017</year><volume>12</volume><issue>11</issue><fpage>e0187376</fpage><?supplied-pmid 29121061?><pub-id pub-id-type="pmid">29121061</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baruah</surname><given-names>UK</given-names></name><name><surname>Gowthamarajan</surname><given-names>K</given-names></name><name><surname>Ravisankar</surname><given-names>V</given-names></name><name><surname>Karri</surname><given-names>V</given-names></name><name><surname>Simhadri</surname><given-names>PK</given-names></name><name><surname>Singh</surname><given-names>V</given-names></name></person-group><article-title>Optimisation of chloroquine phosphate loaded nanostructured lipid carriers using Box-Behnken design and its antimalarial efficacy</article-title><source>J Drug Target</source><year>2018</year><volume>26</volume><issue>7</issue><fpage>576</fpage><lpage>591</lpage><?supplied-pmid 29057679?><pub-id pub-id-type="pmid">29057679</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paton</surname><given-names>NI</given-names></name><name><surname>Lee</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Ooi</surname><given-names>EE</given-names></name><name><surname>Cheung</surname><given-names>YB</given-names></name><name><surname>Archuleta</surname><given-names>S</given-names></name><name><surname>Wong</surname><given-names>G</given-names></name><name><surname>Wilder-Smith</surname><given-names>A</given-names></name></person-group><article-title>Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial</article-title><source>Lancet Infect Dis</source><year>2011</year><volume>11</volume><issue>9</issue><fpage>677</fpage><lpage>683</lpage><?supplied-pmid 21550310?><pub-id pub-id-type="pmid">21550310</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><mixed-citation publication-type="other">Yao X; Ye F; Zhang M.; Cui C; Huang B; Niu P; Liu X; Zhao L; Dong E; Song C; Zhan S; Lu R; Li H; Tan W; Liu D, In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020.</mixed-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Tian</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name></person-group><article-title>Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies</article-title><source>Biosci Trends</source><year>2020</year><volume>14</volume><issue>1</issue><fpage>72</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">32074550</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><mixed-citation publication-type="other">Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi 2020, 43, (0), E019.</mixed-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>P</given-names></name><name><surname>Karako</surname><given-names>T</given-names></name></person-group><article-title>COVID-19: real-time dissemination of scientific information to fight a public health emergency of international concern</article-title><source>Biosci Trends</source><year>2020</year><volume>14</volume><issue>1</issue><fpage>1</fpage><lpage>2</lpage><?supplied-pmid 32092748?><pub-id pub-id-type="pmid">32092748</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><mixed-citation publication-type="other">Hydroxychloroquine. In LiverTox: clinical and research information on drug-induced liver injury, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda (MD), 2012.</mixed-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>C</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Wan</surname><given-names>JP</given-names></name><name><surname>Wen</surname><given-names>C</given-names></name></person-group><article-title>The pharmacological mechanisms and therapeutic activities of hydroxychloroquine in rheumatic and related diseases</article-title><source>Curr Med Chem</source><year>2017</year><volume>24</volume><issue>20</issue><fpage>2241</fpage><lpage>2249</lpage><?supplied-pmid 28302011?><pub-id pub-id-type="pmid">28302011</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schrezenmeier</surname><given-names>E</given-names></name><name><surname>D&#x000f6;rner</surname><given-names>T</given-names></name></person-group><article-title>Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology</article-title><source>Nat Rev Rheumatol</source><year>2020</year><volume>16</volume><issue>3</issue><fpage>155</fpage><lpage>166</lpage><?supplied-pmid 32034323?><pub-id pub-id-type="pmid">32034323</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plantone</surname><given-names>D</given-names></name><name><surname>Koudriavtseva</surname><given-names>T</given-names></name></person-group><article-title>Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review</article-title><source>Clin Drug Investig</source><year>2018</year><volume>38</volume><issue>8</issue><fpage>653</fpage><lpage>671</lpage><?supplied-pmid 29737455?><pub-id pub-id-type="pmid">29737455</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shippey</surname><given-names>EA</given-names></name><name><surname>Wagler</surname><given-names>VD</given-names></name><name><surname>Collamer</surname><given-names>AN</given-names></name></person-group><article-title>Hydroxychloroquine: an old drug with new relevance</article-title><source>Cleve Clin J Med</source><year>2018</year><volume>85</volume><issue>6</issue><fpage>459</fpage><lpage>467</lpage><?supplied-pmid 29883308?><pub-id pub-id-type="pmid">29883308</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khalili</surname><given-names>H</given-names></name><name><surname>Dastan</surname><given-names>F</given-names></name><name><surname>Dehghan Manshadi</surname><given-names>SA</given-names></name></person-group><article-title>A case report of hearing loss post use of hydroxychloroquine in a HIV-infected patient</article-title><source>Daru</source><year>2014</year><volume>22</volume><issue>1</issue><fpage>20</fpage><?supplied-pmid 24450358?><pub-id pub-id-type="pmid">24450358</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>B</given-names></name><name><surname>Parnell</surname><given-names>LA</given-names></name><name><surname>Diamond</surname><given-names>MS</given-names></name><name><surname>Mysorekar</surname><given-names>IU</given-names></name></person-group><article-title>Inhibition of autophagy limits vertical transmission of Zika virus in pregnant mice</article-title><source>J Exp Med</source><year>2017</year><volume>214</volume><issue>8</issue><fpage>2303</fpage><lpage>2313</lpage><?supplied-pmid 28694387?><pub-id pub-id-type="pmid">28694387</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><mixed-citation publication-type="other">Colson P; Rolain JM; Lagier JC; Brouqui P; Raoult D, Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 2020, 105932.</mixed-citation></ref><ref id="CR97"><label>97.</label><mixed-citation publication-type="other">Gautret P; Lagier JC; Parola P; Hoang VT; Meddeb L; Mailhe M; Doudier B; Courjon J; Giordanengo V; Vieira VE; Dupont HT; Honor&#x000e9; S; Colson P; Chabri&#x000e8;re E; La Scola B; Rolain JM; Brouqui P; Raoult D, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020, 105949.</mixed-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Zhong</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name></person-group><article-title>Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro</article-title><source>Cell Discov</source><year>2020</year><volume>6</volume><fpage>16</fpage><?supplied-pmid 32194981?><pub-id pub-id-type="pmid">32194981</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><mixed-citation publication-type="other">Sahraei Z; Shabani M; Shokouhi S; Saffaei A, Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. Int J Antimicrob Agents 2020, 105945.</mixed-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snell</surname><given-names>LM</given-names></name><name><surname>McGaha</surname><given-names>TL</given-names></name><name><surname>Brooks</surname><given-names>DG</given-names></name></person-group><article-title>Type I interferon in chronic virus infection and cancer</article-title><source>Trends Immunol</source><year>2017</year><volume>38</volume><issue>8</issue><fpage>542</fpage><lpage>557</lpage><?supplied-pmid 28579323?><pub-id pub-id-type="pmid">28579323</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><mixed-citation publication-type="other">Sen N; Sung P; Panda A; Arvin AM, Distinctive roles for type I and type II interferons and interferon regulatory factors in the host cell defense against Varicella-Zoster virus. J Virol 2018<bold>,</bold> 92, (21).</mixed-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>HS</given-names></name><name><surname>Kuok</surname><given-names>DIT</given-names></name><name><surname>Cheung</surname><given-names>MC</given-names></name><name><surname>Ng</surname><given-names>MMT</given-names></name><name><surname>Ng</surname><given-names>KC</given-names></name><name><surname>Hui</surname><given-names>KPY</given-names></name><name><surname>Peiris</surname><given-names>JSM</given-names></name><name><surname>Chan</surname><given-names>MCW</given-names></name><name><surname>Nicholls</surname><given-names>JM</given-names></name></person-group><article-title>Effect of interferon alpha and cyclosporine treatment separately and in combination on Middle East respiratory syndrome coronavirus (MERS-CoV) replication in a human in-vitro and ex-vivo culture model</article-title><source>Antivir Res</source><year>2018</year><volume>155</volume><fpage>89</fpage><lpage>96</lpage><?supplied-pmid 29772254?><pub-id pub-id-type="pmid">29772254</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snyder</surname><given-names>B</given-names></name><name><surname>Goebel</surname><given-names>S</given-names></name><name><surname>Koide</surname><given-names>F</given-names></name><name><surname>Ptak</surname><given-names>R</given-names></name><name><surname>Kalkeri</surname><given-names>R</given-names></name></person-group><article-title>Synergistic antiviral activity of sofosbuvir and type-I interferons (&#x003b1; and &#x003b2;) against Zika virus</article-title><source>J Med Virol</source><year>2018</year><volume>90</volume><issue>1</issue><fpage>8</fpage><lpage>12</lpage><?supplied-pmid 28851097?><pub-id pub-id-type="pmid">28851097</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanmart&#x000ed;</surname><given-names>R</given-names></name><name><surname>Ruiz-Esquide</surname><given-names>V</given-names></name><name><surname>Bastida</surname><given-names>C</given-names></name><name><surname>Soy</surname><given-names>D</given-names></name></person-group><article-title>Tocilizumab in the treatment of adult rheumatoid arthritis</article-title><source>Immunotherapy</source><year>2018</year><volume>10</volume><issue>6</issue><fpage>447</fpage><lpage>464</lpage><?supplied-pmid 29495891?><pub-id pub-id-type="pmid">29495891</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>SS</given-names></name><name><surname>Jung</surname><given-names>SM</given-names></name><name><surname>Song</surname><given-names>JJ</given-names></name><name><surname>Park</surname><given-names>YB</given-names></name><name><surname>Park</surname><given-names>JY</given-names></name><name><surname>Lee</surname><given-names>SW</given-names></name></person-group><article-title>Safety of tocilizumab in rheumatoid arthritis patients with resolved hepatitis B virus infection: data from real-world experience</article-title><source>Yonsei Med J</source><year>2018</year><volume>59</volume><issue>3</issue><fpage>452</fpage><lpage>456</lpage><?supplied-pmid 29611409?><pub-id pub-id-type="pmid">29611409</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashizume</surname><given-names>M</given-names></name><name><surname>Tan</surname><given-names>SL</given-names></name><name><surname>Takano</surname><given-names>J</given-names></name><name><surname>Ohsawa</surname><given-names>K</given-names></name><name><surname>Hasada</surname><given-names>I</given-names></name><name><surname>Hanasaki</surname><given-names>A</given-names></name><name><surname>Ito</surname><given-names>I</given-names></name><name><surname>Mihara</surname><given-names>M</given-names></name><name><surname>Nishida</surname><given-names>K</given-names></name></person-group><article-title>Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insights</article-title><source>Int Rev Immunol</source><year>2015</year><volume>34</volume><issue>3</issue><fpage>265</fpage><lpage>279</lpage><?supplied-pmid 25099958?><pub-id pub-id-type="pmid">25099958</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheppard</surname><given-names>M</given-names></name><name><surname>Laskou</surname><given-names>F</given-names></name><name><surname>Stapleton</surname><given-names>PP</given-names></name><name><surname>Hadavi</surname><given-names>S</given-names></name><name><surname>Dasgupta</surname><given-names>B</given-names></name></person-group><article-title>Tocilizumab (Actemra)</article-title><source>Hum Vaccin Immunother</source><year>2017</year><volume>13</volume><issue>9</issue><fpage>1972</fpage><lpage>1988</lpage><?supplied-pmid 28841363?><pub-id pub-id-type="pmid">28841363</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>SA</given-names></name><name><surname>Scheller</surname><given-names>J</given-names></name><name><surname>Rose-John</surname><given-names>S</given-names></name></person-group><article-title>Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling</article-title><source>J Clin Invest</source><year>2011</year><volume>121</volume><issue>9</issue><fpage>3375</fpage><lpage>3383</lpage><?supplied-pmid 21881215?><pub-id pub-id-type="pmid">21881215</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramamoorthy</surname><given-names>S</given-names></name><name><surname>Cidlowski</surname><given-names>JA</given-names></name></person-group><article-title>Corticosteroids: mechanisms of action in health and disease</article-title><source>Rheum Dis Clin N Am</source><year>2016</year><volume>42</volume><issue>1</issue><fpage>15</fpage><lpage>31</lpage></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meijer</surname><given-names>OC</given-names></name><name><surname>Koorneef</surname><given-names>LL</given-names></name><name><surname>Kroon</surname><given-names>J</given-names></name></person-group><article-title>Glucocorticoid receptor modulators</article-title><source>Ann Endocrinol</source><year>2018</year><volume>79</volume><issue>3</issue><fpage>107</fpage><lpage>111</lpage></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whittier</surname><given-names>X</given-names></name><name><surname>Saag</surname><given-names>KG</given-names></name></person-group><article-title>Glucocorticoid-induced osteoporosis</article-title><source>Rheum Dis Clin N Am</source><year>2016</year><volume>42</volume><issue>1</issue><fpage>177</fpage><lpage>189</lpage></element-citation></ref><ref id="CR112"><label>112.</label><mixed-citation publication-type="other">Zhou YH; Qin YY; Lu YQ; Sun F; Yang S; Harypursat V; Tang SQ; Huang YQ; He XQ; Zeng YM.; Li Y; Xu XL; Zhao T; Chen YK, Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: protocol of a randomized controlled trial. Chin Med J 2020.</mixed-citation></ref><ref id="CR113"><label>113.</label><mixed-citation publication-type="other">Guo T; Fan Y; Chen M; Wu X; Zhang L; He T; Wang H; Wan J; Wang X; Lu Z, Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020.</mixed-citation></ref><ref id="CR114"><label>114.</label><mixed-citation publication-type="other">Hu H; Ma F; Wei X; Fang Y, Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J 2020.</mixed-citation></ref><ref id="CR115"><label>115.</label><mixed-citation publication-type="other">Zhang B; Liu S; Tan T; Huang W; Dong Y; Chen L; Chen Q; Zhang L; Zhong Q; Zhang X; Zou Y; Zhang S, Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection. Chest 2020.</mixed-citation></ref></ref-list></back></article>